Colchicine efficacy comparison at varying time points in the peri-operative period for coronary artery disease: a systematic review and meta-analysis of randomized controlled trials

被引:2
作者
Wei, Zhi-Yang [1 ]
Lai, Jun-Yu [2 ]
Li, Ya-Ting [1 ]
Yu, Xiao-Yan [1 ]
Liu, Yan-Hong [1 ]
Hu, Jing-Xuan [1 ]
Gao, Bei-Bei [1 ]
Wu, Jian-Guang [2 ]
机构
[1] Jiangxi Univ Tradit Chinese Med, Dept Postgrad, Nanchang, Peoples R China
[2] Jiangxi Univ Tradit Chinese Med, Affiliated Hosp, Cardiol Dept, Nanchang, Peoples R China
来源
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2023年 / 10卷
关键词
colchicine; coronary artery disease; percutaneous coronary intervention; intervention time point; systematic review; meta-analysis; ACUTE MYOCARDIAL-INFARCTION; IN-STENT RESTENOSIS; C-REACTIVE PROTEIN; INTERVENTION; INFLAMMATION; INTERLEUKIN-6; EXPRESSION; PREVENTION; ELEVATION; OUTCOMES;
D O I
10.3389/fcvm.2023.1156980
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Over the years, it has been found that colchicine offers substantial benefits in secondary prevention in patients with coronary artery disease (CAD). We studied the effects of colchicine timing because there are no guidelines about when to provide it during the perioperative period for patients with CAD. Methods: Up to January 1, 2023, seven electronic literature databases were screened (including three English databases and four Chinese databases). Randomized controlled trials included only treatment with colchicine in the perioperative period of CAD. The Cochrane Evaluation Tool was used to judge the risk of bias in research. Statistical analysis was performed by Stata 16.0 software. Results: We evaluated twelve studies that found colchicine to be effective in decreasing the occurrence of major adverse cardiac events (MACEs) ( p < 0.00001), but it also raised the rate of adverse events ( p = 0.001). Subgroup analysis showed the same benefit in lowering the incidence of MACE with continuous administration of a total daily dose of 0.5 mg postoperatively while minimizing drug-related side effects in the patients ( p = 0.03). When it comes to preventing surgical stroke occurrences, postoperative administration is more effective ( p = 0.006). While the effect of simultaneous preoperative and postoperative administration was marginally greater than other periods in reducing postoperative hs-CRP levels ( p = 0.02). Conclusion: Colchicine, a traditional anti-inflammatory drug, also reduces the risk of MACE by reducing inflammation after PCI. Administration at different periods had no significant effect on decreasing the occurrence of MACE, but when administered postoperatively, we advise continuous administration with a total daily dose of 0.5 mg to obtain the same benefit while minimizing the drug's side effects. Postoperative administration is the better measure to prevent postoperative stroke events. Due to the effective anti-inflammatory effect of colchicine, we recommend its use as early as possible in the perioperative period and its continued use at low doses in the postoperative period.
引用
收藏
页数:17
相关论文
共 59 条
  • [1] Neutrophil α-defensins promote thrombosis in vivo by altering fibrin formation, structure, and stability
    Abu-Fanne, Rami
    Stepanova, Victoria
    Litvinov, Rustem I.
    Abdeen, Suhair
    Bdeir, Khalil
    Higazi, Mohamed
    Maraga, Emad
    Nagaswami, Chandrasekaran
    Mukhitov, Alexander R.
    Weisel, John W.
    Cines, Douglas B.
    Higazi, Abd Al-Roof
    [J]. BLOOD, 2019, 133 (05) : 481 - 493
  • [2] Effect of low-dose colchicine in acute and chronic coronary syndromes: A systematic review and meta-analysis
    Aimo, Alberto
    Figal, Domingo A. Pascual
    Bayes-Genis, Antoni
    Emdin, Michele
    Georgiopoulos, Georgios
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 (04)
  • [3] COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response
    Akodad, Mariama
    Lattuca, Benoit
    Nagot, Nicolas
    Georgescu, Vera
    Buisson, Mathilde
    Cristol, Jean-Paul
    Leclercq, Florence
    Macia, Jean-Christophe
    Gervasoni, Richard
    Thien-Tri Cung
    Cade, Stephane
    Cransac, Frederic
    Labour, Jessica
    Dupuy, Anne-Marie
    Roubille, Francois
    [J]. ARCHIVES OF CARDIOVASCULAR DISEASES, 2017, 110 (6-7) : 395 - 402
  • [4] Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial
    Akrami, Mehdi
    Izadpanah, Peyman
    Bazrafshan, Mehdi
    Hatamipour, Unes
    Nouraein, Navid
    Drissi, Hamed Bazrafshan
    Manafi, Alireza
    [J]. BMC CARDIOVASCULAR DISORDERS, 2021, 21 (01)
  • [5] Colchicine for symptomatic coronary artery disease after percutaneous coronary intervention
    Aw, Kah Long
    Koh, Amanda
    Lee, Han Lin
    Kudzinskas, Aurimas
    De Palma, Rodney
    [J]. OPEN HEART, 2022, 9 (01):
  • [6] Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
    Bouabdallaoui, Nadia
    Tardif, Jean-Claude
    Waters, David D.
    Pinto, Fausto J.
    Maggioni, Aldo P.
    Diaz, Rafael
    Berry, Colin
    Koenig, Wolfgang
    Lopez-Sendon, Jose
    Gamra, Habib
    Kiwan, Ghassan S.
    Blondeau, Lucie
    Orfanos, Andreas
    Ibrahim, Reda
    Gregoire, Jean C.
    Dube, Marie-Pierre
    Samuel, Michelle
    Morel, Olivier
    Lim, Pascal
    Bertrand, Olivier F.
    Kouz, Simon
    Guertin, Marie-Claude
    L'Allier, Philippe L.
    Roubille, Francois
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 (42) : 4092 - 4099
  • [7] Treating Inflammation Prior to Percutaneous Coronary Intervention Does the Heart Care?
    Cao, Davide
    Chiarito, Mauro
    Mehran, Roxana
    [J]. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2020, 13 (04)
  • [8] Both Low and High Postprocedural hsCRP Associate with Increased Risk of Death in Acute Coronary Syndrome Patients Treated by Percutaneous Coronary Intervention
    Chen, Runzhen
    Liu, Chen
    Zhou, Peng
    Tan, Yu
    Sheng, Zhaoxue
    Li, Jiannan
    Zhou, Jinying
    Chen, Yi
    Song, Li
    Zhao, Hanjun
    Yan, Hongbing
    [J]. MEDIATORS OF INFLAMMATION, 2020, 2020
  • [9] Colchicine to Prevent Periprocedural Myocardial Injury in Percutaneous Coronary Intervention The COPE-PCI Pilot Trial
    Cole, Justin
    Htun, Nay
    Lew, Robert
    Freilich, Mark
    Quinn, Stephen
    Layland, Jamie
    [J]. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2021, 14 (05) : 483 - 490
  • [10] Collet JP, 2021, REV ESP CARDIOL, V74, DOI [10.1093/eurheartj/ehaa575, 10.1016/j.rec.2021.05.002]